Advanced Search

 

Study ID Status Title Patient Level Data
208821 Completed A single dose, open label, randomized scintigraphic study to investigate the gastrointestinal behavior of 2 triple combination products (Acetaminophen, Phenylephrine and Dextromethorphan) in healthy male volunteers
208854 Not yet recruiting Retrospective, observational, cohort study to assess the persistence and adherence to Duodart vs concomitant therapy of alpha blocker (AB) plus 5-alphareductase inhibitor (5-ARI) in German BPH-patients
208901 Recruiting A Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Steady-State Pharmacokinetic and Disposition Study Characterizing Diclofenac’s Plasma and Knee Exposure in Osteoarthritis (OA) Subjects Undergoing Scheduled Arthroplasty after Treatment with Diclofenac Diethylamine (DDEA) 2.32% Gel
209018 Not yet recruiting Asthma Exacerbations and Costs- Xolair 12 Months Pre- & Post- Administration
209019 Not yet recruiting Patient Characteristics and Medical Utilization of Nucala in an Employer Claims Database
209020 Completed A network meta-analysis comparing anti-IL5 treatments in severe eosinophilic asthma using aggregate data
209135 Not yet recruiting PGx7692_GSK2834425, GSK2285997, GSK2592356, GSK573719, GW685698, GW642444_Exploratory evaluation of the role of genetic variation in efficacy response to Trelegy and its component parts in COPD subjects
209261 Not yet recruiting A two part, non-randomised, open label study designed to assess the pharmacokinetic profile of modified release prototype coated tablet formulations of GSK2982772 relative to an immediate release reference tablet formulation at a fixed strength (Part A) and the pharmacokinetic profile of alternative tablet strengths of the selected modified release prototype coated tablet formulation (Part B, optional) in healthy participants
209275 Recruiting A Three-Part FTIH Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Oral Doses of GSK3439171A, in a Randomized, Double-Blind (sponsor unblinded), Placebo-Controlled, Dose Escalation study and to Evaluate the Effect of Food on a Single Oral Dose of GSK3439171A in Healthy Adult Participants
209304 Recruiting Meta-Analysis Plan for 209304 (DB2113361 and DB2113373): Phase III Efficacy and Safety Studies of GSK573719 (umeclidinium)/GW642444 (vilanterol) Inhalation Powder Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease
209322 Recruiting Meta-Analysis plan for 209322: Influence of smoking status on the efficacy of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD in two Randomized, multi-center, double-blind, double dummy, parallel group studies (DB2114930 and DB2114951)
209422 Not yet recruiting Costs and Healthcare Resource Utilization Associated with Systemic Lupus Erythematosus (SLE) Flares and Belimumab Utilization Among Patients with SLE
209442 Not yet recruiting A Clinical Study to Assess the Local Cutaneous and Ocular Tolerance of a Developmental Cosmetic Facial Serum Formulation in Healthy Females with Sensitive Skin
209509 Not yet recruiting A Post-hoc Pooled Analysis of GSK CH Clinical Data Investigating the Efficacy of a Dentifrice containing 67% w/w Sodium Bicarbonate on Gingivitis and Plaque Accumulation
209762/147 Completed Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18 months in Singapore. Study Listed on ClinicalStudyDataRequest.com
210042 Not yet recruiting Meta-Analysis Plan for 209652: A Meta-Analysis to Evaluate the Effect of Active Interventions vs Placebo or Usual Care on the Rate of Decline in FEV1 in participants with Chronic Obstructive Pulmonary Disease (COPD)
210602-002 Completed Assess the feasibility of an investigational vaccination regimen, compared to a 3-dose primary vaccination with GSK Biologicals' Infanrix hexa™ (DTPa-HBV-IPV/Hib vaccine) following hepatitis B vaccination at birth. Primary vaccination is followed in the 2nd year of life by a booster dose of Infanrix-hexa Study Listed on ClinicalStudyDataRequest.com
213503/047 Completed Open, randomized, phase II, clinical trial to compare the immunogenicity and safety of a booster dose of GSK Biologicals' DTaP-IPV vaccine (Infanrix®-IPV) co-administered with a booster dose of Merck and Company's M-M-R®II, to that of separate injections of GSK Biologicals' DTaP vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II administered as booster doses to healthy children 4 to 6 years of age. Study Listed on ClinicalStudyDataRequest.com
213503/048 Completed Safety, immunogenicity&consistency of 3 manufacturing lots of DTaP-IPV vaccine vs separate injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV admd as booster doses to healthy children 4-6 yrs, each co-admd with Merck's MMR vaccine Study Listed on ClinicalStudyDataRequest.com
217744/031 Completed Study to assess immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ DTPa-HBV-IPV/Hib vaccine given as three-dose primary vaccination course compared to DTPa-IPV/Hib and HBV administered concomitantly at separate sites
217744/049 Completed Immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV and Hib vaccines when administered concomitantly to healthy infants administered as a three-dose primary vaccination course at the age of 1.5, 3.5 and 6 months Study Listed on ClinicalStudyDataRequest.com
217744/054 Completed Study to assess the immunogenicity and reactogenicity of DTPa-HBV-IPV vaccine mixed with Hib vaccine to healthy infants at 3, 5 and 11 months of age, compared to each vaccine administered separately
217744/060 Completed Study to assess the immunogenicity and reactogenicity of DTPa-HBV-IPV mixed with Hib vaccine in healthy infants, followed by a dose of the same vaccine administered simultaneously with one dose of oral polio vaccine (OPV) Study Listed on ClinicalStudyDataRequest.com
217744/069 Completed Immunogenicity and safety of GSK Biological’s DTPa-HBV-IPV/Hib vaccine or DTPa-IPV/Hib co-administered with HBV vaccine as primary and booster vaccination in healthy infants born to hepatitis B surface antigen negative mothers Study Listed on ClinicalStudyDataRequest.com
217744/075 Completed Phase III, open, randomised immunogenicity and reactogenicity study to assess the interchangeability between GSK Bios' DTPa-HBV-IPV/Hib and DTPa-IPV/Hib + HBV at 3rd dose of primary vac. course in children who received HBV vac. at birth and one month of age and DTPa-IPV/Hib vac at 3-4 Mth of age Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.